| Active substance | finerenone |
| Holder | Bayer |
| Status | closed |
| Indication | Adult patients with chronic kidney disease (CKD) (stage 3 & 4 with albuminuria) associated with type 2 diabetes (T2D) who cannot be satisfactorily treated with the standard of care. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 30/01/2023 |